STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease

STAT News

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine. ...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

관련 뉴스

관련 뉴스 제보는 로그인 후 가능합니다.

'science' 카테고리 뉴스

Most breastfeeding mothers take medication, but many are making decisions without good information

Medical Xpress

Teens want more advice about navigating consent but teachers' sex ed skills are falling short

Phys.org

New snail species bolster case for protecting Montenegro's biodiversity

Phys.org

STAT의 다른 기사

STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive

STAT News

STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more

STAT News

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

STAT News